- Home
- GDV vs KNSA Comparison
GDV vs KNSA Comparison
Compare GDV & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDV
- KNSA
- Stock Information
- Founded
- GDV 2003
- KNSA 2015
- Country
- GDV United States
- KNSA United Kingdom
- Employees
- GDV N/A
- KNSA N/A
- Industry
- GDV Investment Managers
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- GDV Finance
- KNSA Health Care
- Exchange
- GDV Nasdaq
- KNSA Nasdaq
- Market Cap
- GDV 2.2B
- KNSA 2.1B
- IPO Year
- GDV N/A
- KNSA 2018
- Fundamental
- Price
- GDV $26.26
- KNSA $27.13
- Analyst Decision
- GDV
- KNSA Strong Buy
- Analyst Count
- GDV 0
- KNSA 5
- Target Price
- GDV N/A
- KNSA $38.80
- AVG Volume (30 Days)
- GDV 186.0K
- KNSA 1.1M
- Earning Date
- GDV 01-01-0001
- KNSA 07-22-2025
- Dividend Yield
- GDV 5.81%
- KNSA N/A
- EPS Growth
- GDV N/A
- KNSA N/A
- EPS
- GDV N/A
- KNSA N/A
- Revenue
- GDV N/A
- KNSA $481,166,000.00
- Revenue This Year
- GDV N/A
- KNSA $37.21
- Revenue Next Year
- GDV N/A
- KNSA $5.32
- P/E Ratio
- GDV N/A
- KNSA N/A
- Revenue Growth
- GDV N/A
- KNSA 59.45
- 52 Week Low
- GDV $18.04
- KNSA $17.38
- 52 Week High
- GDV $23.00
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- GDV 74.91
- KNSA 44.42
- Support Level
- GDV $24.57
- KNSA $27.08
- Resistance Level
- GDV $25.29
- KNSA $28.86
- Average True Range (ATR)
- GDV 0.28
- KNSA 1.04
- MACD
- GDV 0.09
- KNSA -0.32
- Stochastic Oscillator
- GDV 97.24
- KNSA 16.05
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.